(Q33876942)

English

Statins: effective antiatherosclerotic therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

Statins: effective antiatherosclerotic therapy (English)

1 reference

Europe PubMed Central

29 July 2017

author name string

Blumenthal RS

1

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

1 April 2000

1 reference

Europe PubMed Central

29 July 2017

American Heart Journal

1 reference

Europe PubMed Central

29 July 2017

139

1 reference

Europe PubMed Central

29 July 2017

577-583

1 reference

Europe PubMed Central

29 July 2017

4

1 reference

Europe PubMed Central

29 July 2017

Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Effects of simvastatin on apoB metabolism and LDL subfraction distribution

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Natural statins and stroke risk.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: Comparison with selected HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Comparison of statins in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

A modern view of atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

HMG-CoA Reductase Inhibitors Decrease CD11b Expression and CD11b-Dependent Adhesion of Monocytes to Endothelium and Reduce Increased Adhesiveness of Monocytes Isolated From Patients With Hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Regulation of the mevalonate pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2800%2990033-4

7 January 2021

Identifiers

10.1016/S0002-8703(00)90033-4

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33876942&oldid=1964719679"